GARDP’s pipeline (Sep 2021)

- **SERIOUS BACTERIAL INFECTIONS**
  - Cefepime-taniborbactam (NCE) Venatorx Pharmaceuticals
    - Approved in EU, with Neo & Paeds label
    - Approved in Asia: Neo & Paeds data
    - Approved globally: Neo & Paeds data
    - Approved in USA, with limited Neo & Paeds label
  - Potential candidate A (NCE or repurposed)
  - IV Fosfomycin
  - Flomoxef
  - Amikacin
  - Polymyxin B*

- **NEONATAL SEPSIS**
  - Paediatric cefepime-taniborbactam (NCE) Venatorx Pharmaceuticals
  - Potential candidate A (NCE or repurposed)
  - Treatment regimens
    - Public health strategic efficacy and safety trials
  - Regulatory paediatric plans
    - (serious bacterial infections paediatric and neonates)

- **SEXUALLY TRANSMITTED INFECTIONS**
  - Zoliflodacin (NCE) Entasis Therapeutics Inc.
    - Approved in USA / EU for CABP
  - Potential candidate B (NCE)

---

* Under review / on-hold
** Development of cefepime-taniborbactam is sponsored by Venatorx Pharmaceuticals and has been funded in whole or in part with federal funds from NIAID/NIH/HHS and BARDA/ASPR/HHS in the United States and The Welcome Trust in the United Kingdom
*** Potential pipeline addition, MOU signed between GARDP, Shionogi and Clinton Health Access Initiative (CHAI) to explore Cefiderocol access in LMICs